No Prescription |
 |
 | ||
|
IPSITA ATACAND |
|
| ||
No Prescription » Prescription Drugs 9 » IPSITA ATACAND Candesartan is used to treat high blood pressure. It blocks the action of certain chemicals that tighten the blood vessels so blood flows more smoothly.Candesartan comes as a tablet to take by mouth. It is usually taken once or twice a day with or without food. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take candesartan exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Candesartan controls high blood pressure but does not cure it. Continue to take candesartan even if you feel well. Do not stop taking candesartan without talking to your doctor. Buy IPSITA ATACAND and other Prescription Drugs 9 products online at Medstore. 393
About IPSITA ATACAND: Product Type: Prescription Drugs 9 IPSITA ( ATACAND Generic CANDESARTAN ) IPSITA (ATACAND Generic CANDESARTAN) ATACAND Generic CANDESARTAN 16mg 10 tablets ATACAND Generic CANDESARTAN IPSITA
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
